Gyre Therapeutics (NASDAQ:GYRE) Trading Up 7.6% – Here’s Why

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded up 7.6% on Tuesday . The company traded as high as $11.45 and last traded at $11.35. Approximately 12,713 shares changed hands during trading, a decline of 84% from the average session volume of 78,660 shares. The stock had previously closed at $10.55.

Gyre Therapeutics Trading Up 6.9 %

The company has a 50-day moving average price of $11.41 and a two-hundred day moving average price of $12.33.

Insiders Place Their Bets

In other news, President Songjiang Ma sold 2,000 shares of the stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 30,054 shares of company stock worth $342,277 in the last three months. 19.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors have recently modified their holdings of GYRE. FMR LLC bought a new position in Gyre Therapeutics in the 3rd quarter worth $47,000. Wells Fargo & Company MN raised its stake in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after buying an additional 913 shares in the last quarter. Bank of America Corp DE lifted its holdings in Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares during the period. Barclays PLC boosted its position in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after acquiring an additional 1,389 shares during the period. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.